{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"210"}],"units":"Participants"}],"description":"Percentage of study participants who experienced a serious adverse event (SAE) within 1 year of bone marrow transplant. Complete data is provided in the Adverse Event tables.","groups":[{"description":"Non-myeloablative haploidentical bone marrow transplant with a fludarabine, cyclophosphamide (Cy), TBI (total body irradiation) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.","id":"OG000","title":"Mini-haplo BMT"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year","title":"Hematologic and Non-hematologic Toxicities as Measured by NCI Common Toxicity Criteria for Adverse Events, v 3.0 Weekly Until 1 Year After Transplantation","type":"SECONDARY","unitOfMeasure":"percentage of participants"}